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Abstract
Background: Breast milk is a complex liquid that provides nutrition to the infant and facilitates the maturation of
the infant’s immune system. Recent studies indicated that microRNA (miRNA) exists in human body fluid. Because
miRNAs are known to regulate various immune systems, we hypothesized that human breast milk contains miRNAs
that may be important for the development of the infant’s immune system.
Findings: We profiled miRNA expression in human breast milk and detected high expression levels of immune-
related miRNAs in the first 6 months of lactation. Furthermore, these miRNA molecules are stable even in very
acidic conditions, indicating that breast milk allows dietary intake of miRNAs by infants.
Conclusions: Our findings provide new insight into how breast milk can modulate the development of the infant’s
immune system. This study suggests the transfer of genetic material as miRNA from human to human occurs by
means other than through sexual reproduction.
Introduction
The mammary glands of mammals are specialized
organs whose function is to produce milk, the primary
source of nutrition for newborns. Breastfeeding is recog-
nized as one of the most valuable contributors to infant
health [1]. Human breast milk protects infants not only
against infections but also against chronic diseases.
Furthermore, human breast milk contains certain
growth factors that help the infant intestine to develop,
become able to absorb milk and prepare for food intake.
When maternal breast milk is unavailable, the alterna-
tive is infant formula. Compared with infants fed on for-
mula, infants fed on breast milk have a lower incidence
of digestive problems and are more likely to be pro-
tected against gastrointestinal and respiratory infections.
Despite the fact that breastfeeding is known to be the
best method for nourishing infants, how exactly breast-
feeding works to provide the best nutrition and protect
infants against disease is not fully understood.
Many immune-related substances are present in
human breast milk, and their effects upon the recipient
infants are widely recognized [2,3]. For instance, human
breast milk contains large quantities of secretory (s)IgA.
These antibodies can bind to pathogens and prevent
their attachment to an infant’s cells. Furthermore,
human breast milk contains measurable levels of leuko-
cytes. In addition to these immunologic components,
breast milk contains several nonspecific factors, such as
lysozyme, lactoferrin and oligosaccharides, which have
antimicrobial effects. Lysozyme inhibits the growth of
many bacterial species by disrupting the proteoglycan
layer of the bacterial cell wall. Lactoferrin, known as a
multifunctional protein in human breast milk, also limits
bacterial growth by removing essential iron and by sti-
mulating cytokine production, and enhancing mucosal
immunity, natural killer (NK) cell activity and macro-
phage cytotoxicity. Substantial amounts of oligosacchar-
ides in the mammary gland were found in human breast
milk, and these block attachment of microbes to an
infant’s mucosa, preventing infections. Nucleotides in
human breast milk have been shown to enhance the
immune function in infants [4]. However, several addi-
tional immune regulatory components in milk may
explain why breastfeeding can reduce infant mortality.
MicroRNAs (miRNAs) are small regulatory RNA
molecules that modulate the activity of specific mRNA
targets and play important roles in a wide range of phy-
siologic and pathologic processes [5-7]. Specific miRNAs
that play important roles in a wide range of physiologic
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and pathologic processes in mammals may be involved
in the control of immunologic reactions [6,7]. A loss-of-
function approach indicated that miRNAs are crucially
involved in the in vivo control of immune regulation
including cellular differentiation and immune response
[8-10]. Recently, miRNAs have been found in serum,
plasma and other body fluids [11-13]. Serum miRNAs
can serve as potential biomarkers for the detection of
various cancers and other diseases. Furthermore, it was
reported that miRNAs circulate in plasma microvesicles
in peripheral blood in healthy people [14]. The majority
of the plasma microvesicles from normal individuals are
derived from blood cells. However, the physiologic roles
of body fluid miRNAs are undetermined. In this report,
we show that a considerable number of miRNAs, espe-
cially those that function in the immune system, are
found in human breast milk. Furthermore, we detected
a higher expression of immune-related miRNAs in the
first 6 months of lactation. These miRNAs are stable
even under harsh conditions. Our findings suggest that
human breast milk contains miRNAs capable of transfer
to immune cells to support the development of an
infant’s immune system.
Results
Extraction of RNAs and expression analysis
To verify the existence of miRNAs in human breast
milk, we extracted total RNA from human breast milk.
miRNAs were detected in each individual at concentra-
tions ranging from 9.7 ng/ml to 228.2 ng/ml. The sam-
ples contained a substantial amount of RNA, but no or
only very low amounts of ribosomal RNA (18S and 28S)
(Figure 1a). Furthermore, large amounts of small RNA
(<300 nucleotides) were detected in the milk.
Next we performed a miRNA microarray to show the
existence of miRNAs in the milk. Using microarray
analysis, 281 of 723 known human miRNAs were
detected. Interestingly, several immune-related miR-
NAs were abundant in the milk (Figure 1b): miR-155,
a regulator of T- and B-cell maturation and the innate
immune response; miR-181a and miR-181b, regulators
of B-cell differentiation and CD4+ T-cell selection;
miR-17 and miR-92 cluster: a ubiquitous regulator of
B-cell, T-cell and monocyte development, miR-125b, a
negative regulator of tumor necrosis factor-a produc-
tion, activation and sensitivity; miR-146b, a negative
regulator of the innate immune response; miR-223, a
regulator of neutrophil proliferation and activation;
and let-7i, a regulator of Toll-like receptor 4 expres-
sion in human cholangiocytes. By contrast, T- and
B-cell regulatory miR-150 was not detected, and sev-
eral tissue-specific miRNAs, such as miR-122
(liver), miR-216, miR-217 (pancreas) and miR-142-5p
and miR-142-3p (hematopoietic cells), were barely
detectable (Figure 1b). Furthermore, the expression
pattern of miRNA within different breast milk samples
from the same mother did not differ greatly with time
after birth (Figure 1c, d). Between individuals, however,
there was more variation. Notably, we detected higher
expression of several immune system-related miRNAs
from human breast milk in the first 6 months, which
is the period before infants receive complementary
food (Figure 2).
Resistance and stability of miRNAs
The existence of RNase in body fluids is already known
[13], and thus there should be no intact RNA present.
The presence of miRNAs suggests that these miRNA
species are resistant to RNase digestion. To prove this
possibility, human breast milk was treated with RNase
A/T.
Strikingly, treatment with RNase had hardly any effect
on human breast milk miRNAs (Figure 3a). By contrast,
the profile of total RNA from that milk and exogenously
added synthetic miRNAs were degraded by the same
treatment (data not shown). These data clearly demon-
strate that human breast milk miRNAs are resistant to
RNase digestion.
Their stability was further studied after treatment
under harsh conditions including freeze-thaw cycles and
low pH. The samples were analyzed by quantitative
reverse transcription (qRT)-PCR analysis.
Results of qRT-PCR analysis of miRNAs in human
breast milk samples subjected to harsh conditions were
not significantly different from samples not subjected to
these conditions. As shown in Figure 3b, human breast
milk miRNAs were resistant to several freeze-thaw
cycles. Moreover, human breast milk miRNAs were
stable when the milk was treated for 1 h in an acidic
(pH 1) solution (Figure 3c).
Existence of microvesicles
Observation of the stability of human breast milk miR-
NAs in vitro suggests the possibility that they are con-
tained within microvesicles or exosomes [14]. To verify
this, we isolated the CD63-positive exosome fraction
and investigated miRNA expression.
As shown in Figure 3d, miR-181a and miR-17, which
we detected by microarray analysis, were also detected
in the CD63-positive exosome fraction. However, it is
still possible that other miRNA protection mechanisms,
such as an apoptotic body, may protect miRNA from
harsh conditions.
Presence of miRNAs in other body fluids
It was previously reported that miRNAs are also
detected in serum samples [11-13]. To investigate differ-
ences in miRNA expression in different body fluids, we
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Figure 1 Expression profile of miRNAs in human breast milk. (a) RNA isolation from breast milk. RNA from breast milk was detected using a
Bioanalyzer. The milk contains a substantial amount of small RNA (<300 nt), but very little or no ribosomal RNA (18S and 28S rRNA). (b–d)
Expression profiling of miRNAs in human breast milk from miRNA microarray. (b) miRNAs in breast milk that were detected or hardly detected
by microarray analysis. (c) Upper panel: a clustering analysis of the expression of breast milk miRNAs before and after the infants received
complementary food. Samples 1, 2 and 3 were from different mothers. Breast milk samples were taken during the first 6 months after birth (0–6)
and during the subsequent months (6+). Lower panel: Strongly expressed miRNA in breast milk before and after the infants received
complementary food. (d) Correlation of gene expression signals between samples obtained from the same mother during the first 6 months
and during the following 6 months are shown. The relationship between samples from different mothers was not as close.
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Figure 2 Comparison by qRT-PCR of immune-related miRNAs in the breast milk obtained before 6 months of age (n = 5) (before the
infants received complementary food) and from 6 to 12 months of age (n = 13) (when infants were receiving complementary food).
Figure 3 General characterization of miRNAs in breast milk. (a–c) The stability of breast milk miRNAs. Total RNA was extracted and then
analyzed by qRT-PCR. Breast milk was (a) incubated with RNase A/T for 3 h at 37°C, (b) subjected to three freeze-thaw cycles or (c) treated for
3 h in a low pH solution (pH 1) before RNA extraction. Representative data are shown. (d) Expression of miR-181a and miR-17 derived from
CD63-positive exosomes isolated from human breast milk (0.3 ml) from different mothers (n = 4). Human breast milk was immunoprecipitated
with anti-CD63 antibody or isotype control.
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analyzed expression of several immune-regulated miR-
NAs in human serum and human breast milk.
Interestingly, the granulocyte-regulated miRNA, miR-
223, is the most strongly expressed miRNA in normal
human plasma, but its expression in breast milk is low
compared with that in serum (Figure 4) [14]. On the
other hand, breast milk is rich in miR-181 and miR-
155, and these were detected at similar levels in serum.
Furthermore, miRNA microarray analysis revealed that
expression of miR-146a, which is high in plasma, was
not found in breast milk, whereas miR-146b, which is
not abundant in plasma was abundantly expressed in
breast milk (Figure 1b).
Discussion
There are several reports in the literature showing the pre-
sence of miRNAs in body fluids including blood plasma/
serum, saliva and urine [11-13]. These studies showed the
usefulness of miRNAs as a biomarker for disease, but did
not investigate any biologic function of the miRNAs in
body fluid. Furthermore, because the function of breast
milk is to provide nutrition to infants from mothers,
miRNA could also have functions in an infant’s body.
In our study, miRNAs in breast milk were stable even
under very acidic conditions (pH 1). This suggests that
these molecules can tolerate an infant’s gastrointestinal
environment and be absorbed in to the intestine, thus
influencing the immune system, as the intestine is one
of their major immune organs (Figure 3c). The storage
and freeze-thawing of breast milk did not denature the
miRNAs, a dietetically important finding for low-birth-
weight babies and other hospitalized infants who are
usually given freezer-stored breast milk (Figure 3b). The
resistance of the miRNAs to the RNase treatment indi-
cated that the miRNAs in human breast milk might be
packaged inside complexes such as exosomes or micro-
vesicles (Figure 3a) [14,15]. Furthermore, as shown in
Figure 3d, we detected miR-181a and miR-17 in a
CD63-positive fraction from human breast milk. A pre-
vious report suggested that breast milk-derived exo-
somes can increase the number of Foxp3+ CD4+ CD25+
regulatory T cells in infants [16]. This is consistent with
our results, showing that human breast milk is rich in
T-cell-regulating miRNAs [17,18]. Furthermore, human
breast milk miRNAs may induce B-cell differentiation,
because the milk is rich in miR-181 and miR-155, both
Figure 4 Immune-related miRNA levels in human breast milk (n = 5) and serum (n = 6) of healthy subjects measured by qRT-PCR.
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known to induce B-cell differentiation [19,20], but it is
not rich in miR-150, which suppresses B-cell differen-
tiation [21,22]. Our miRNA microarray detected many
different types of miRNAs in human breast milk
(Figure 1c); however, the functions of many of these
are still unknown. Because immune-related miRNAs
are well studied and their functions are clarified in the
present report, we focused on their presence in human
breast milk in which we believe miRNAs should have
many more functions, especially in immunologic condi-
tions such as allergy, including atopy and asthma
[23,24].
The transfer of miRNA among cells means that
miRNA is not only a regulatory molecule within the
cell, but also, like cytokines, is a regulatory molecule for
cell-cell communication. Our study clearly suggests that
miRNA is a transferable genetic material from mother
to infant. It is estimated that approximately 1.3 × 107
copies/liter/day of miR-181a are received by a breastfed
infant. Further studies are needed to examine the poten-
tial clinical use of immune-related miRNAs in breast
milk and the mechanisms by which these miRNAs act
as a tool for molecular communication between mother
and infant (Figure 5). As shown in Figure 1c, although
there was more variation between individuals, the
expression pattern of miRNA in human breast milk
samples from the same mother did not differ much with
time after birth. These observations suggest that human
breast milk reflects a mother’s constitution and her liv-
ing environment such as food intake and climate. The
present study provides insight into how breast milk may
protect infants from various infections; proposing that
the miRNAs there act as immune-regulatory agents.
Materials and methods
Ethics statement
All the women gave their signed informed consent to
participate. The study was approved by Dr. Tadao Ishii,
Figure 5 Exosome-like vesicles from human breast milk display the typical size (30–300 nm) and ultrastructure of electron-dense and
electron-lucent microvesicles (arrows). miRNAs in the vesicles within breast milk are received by infants and facilitate many aspects of the
infant’s development. Scale bar, 100 nm.
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Manager of Morinaga Co., Ltd and the company’s ethics
committee (the Ethical Committee of Functional Food
Creation).
Sample collection
Human breast milk samples were collected from eight
women enrolled in a breastfeeding study at Morinaga
Milk Industry Co., Ltd. Human breast milk samples
were collected when the infant were aged between
4 days and 11 months (see Table 1). The milk was col-
lected and then the collected samples totaling 50-100 ml
were put into in storage bags. All samples were stored at
- 80°C until analyzed.
Sample preparation
We chose the samples given <6 months after birth and
samples given between 6 and 12 months after birth.
Cells and large debris within the breast milk were
removed by centrifugation at 2,000 × g for 10 min
twice; the supernatant was then centrifuged at 12,000 ×
g for 30 min to remove cellular debris. The clear super-
natants were used for the analysis.
Total RNA extraction
Total RNA from breast milk was extracted using a mir-
Vana miRNA isolation kit (Ambion, Austin, TX, USA).
Breast milk was thawed on ice, diluted with two
volumes of mirVana Lysis/Binding Solution, mixed thor-
oughly by vortex for 30 s and incubated for 5 min.
Then 1/10 volumes of miRNA homogenate additive was
added, mixed thoroughly by vortex for 30 s and incu-
bated on ice for 10 min. An equal volume of acid/phe-
nol/chloroform (Ambion) was then added to each
aliquot. The resulting solutions were mixed by vortex
for 1 min and spun for 10 min at 10,000 × g. The
resulting aqueous volume was mixed thoroughly with
1.25 volumes of 100% molecular-grade ethanol and
passed through a mirVana column in sequential 700 μl
aliquots. The column was washed according to the man-
ufacturer’s protocol, and RNA was eluted in nuclease-
free water at 95°C. RNA extraction from the serum was
performed using the same method.
Microarray analysis
To detect the expression of miRNAs in human breast
milk, 70 ng of total RNA was labeled and hybridized
using a Human microRNA Microarray Kit (Agilent
Technologies) according to the manufacturer’s protocol
(Protocol for Use with Agilent Microrna Microarrays
Version 1.5). Hybridization signals were detected by a
DNA microarray scanner (Agilent Technologies), and
the scanned images were analyzed using Agilent Feature
Extraction software.
qRT-PCR
qRT-PCR of miRNA expression was performed using
the TaqMan MicroRNA Assay (Applied Biosystems,
Foster City, CA, USA), according to the manufacturer’s
protocol. To normalize the sample-to-sample variation
in the RNA isolation step, synthetic Caenorhabtidis ele-
gans miRNA cel-miR-39 (synthetic RNA oligonucleo-
tides synthesized by Qiagen, Valencia, CA, USA) was
added as a mixture of 25 fmol of each oligonucleotide
in a total volume of 1 ml to each denatured sample
(that is, after combining the breast milk and serum sam-
ples with Lysis Solution (mirVana miRNA isolation kit;
Ambion). All experiments were repeated three times.
RNase and freeze-thawing treatment
To confirm that the miRNA is resistant to RNase diges-
tion, human breast milk was treated with 10 U/ml
RNase A and 400 U/ml RNase T1 (Ambion) for 60 min
at 37°C. After these treatments, the RNA was extracted
from the milk as described above.
To investigate the stability of miRNAs in human
breast milk, the milk was subjected to three freeze-thaw
cycles of at -20°C or treated for 3 h in a low pH solu-
tion (pH 1). miRNA levels were assessed by TaqMan
qRT-PCR.
Isolation of CD63 positive exosome
Exosomes in human breast milk were specifically iso-
lated by magnetic beads, using anti-CD63 antibody (BD,
Erembodgem, Belgium). Human breast milk (0.3 ml)
was incubated with anti-CD63 antibody (BD) or mouse
IgG1 (Sigma-Aldrich, St Louis, MO, USA) coupled to
magnetic microbeads (50 μl). These were mixed and
incubated for 16 h at room temperature. The magnetic
immune complexes were washed four times with 500 μl
of PBS, then the RNA was extracted as described above.
Transmission electron microscopy
Clear supernatants from human breast milk were centri-
fuged at 100,000 × g for two hours, then washed in
phosphate-buffered saline (PBS) and pelleted by ultra-
centrifugation (100,000 × g). The pellet was diluted in
PBS. Resuspended exosomes were fixed in 1% glutaral-
dehyde in PBS (pH 7.4). The samples were stained for
Table 1 Time of sample collection
Volunteer Sample collection (months after birth)
1 6, 8, 8
2 4, 6, 7
3 6, 7, 8, 8
4 7, 7, 8, 9
5 9, 10
6 4 samples within 1 month
7 No information
8 2, 4, 10, 12
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10 min with 1% uranyl acetate. Excess fluid was
removed with a piece of Whatman filter paper. All
transmission electron micrographs were obtained using
JEM1220 electron microscopy at 120 kv.
Acknowledgements
We thank Nami Kosaka and Kenji Kosaka for their help with these studies.
We thank Dr T. Shinoda for providing serum samples. This work was
supported in part by a Grant-in-Aid from the Third-Term Comprehensive 10-
Year Strategy for Cancer Control from the Ministry of Health, Labour, Welfare
of Japan (H21-001); the Program for Promotion of Fundamental Studies in
Health Sciences of the National Institute of Biomedical Innovation (NiBio) (ID
05-31, 08-02); a Takeda Science Foundation grant, and a Grant for Research
Fellowships from the Japan Society for the Promotion of Science for Young
Scientists.
Author details
1Section for Studies on Metastasis, National Cancer Center Research Institute,
1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. 2Nutritional Science
Laboratory, Morinaga Milk Industry Co., Ltd 1-83, 5-chome, Higashihara,
Zama, Kanagawa 228-8583, Japan.
Authors’ contributions
NK designed and performed the experiments and wrote the manuscript. HI
and KS prepared the samples and helped to draft the manuscript. TO
designed experiments and wrote the manuscript. All authors read and
approved the final manuscript.
Competing interests
The Morinaga Milk Industry Co., Ltd is a commercial for-profit company. HI
and KS are employed/funded by salaries from Moringa Milk Industry Co., Ltd.
The Morinaga Milk Industry Co., Ltd has filed patent applications on aspects
of this work. NK, KS, HI and TO are named as inventors with the Morinaga
Milk Industry Co., Ltd on patent application number 2009-165991/July14,
2009.
Received: 21 September 2009 Accepted: 1 March 2010
Published: 1 March 2010
References
1. Hoddinott P, Tappin D, Wright C: Breast feeding. BMJ 2008, 336:881-887.
2. Goldman AS: The immune system in human milk and the developing
infant. Breastfeed Med 2007, 2:195-204.
3. Newburg DS, Walker WA: Protection of the neonate by the innate
immune system of developing gut and of human milk. Pediatr Res 2007,
61:2-8.
4. Carver JD, Pimentel B, Cox WI, Barness LA: Dietary nucleotide effects upon
immune function in infants. Pediatrics 1991, 88:359-363.
5. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. Nat Rev
Mol Cell Biol 2009, 10:126-139.
6. Xiao C, Rajewsky K: MicroRNA control in the immune system: basic
principles. Cell 2009, 136:26-36.
7. Tili E, Michaille JJ, Calin GA: Expression and function of micro-RNAs in
immune cells during normal or disease state. Int J Med Sci 2008, 5:73-79.
8. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A,
Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N,
Yancopoulos G, Rao A, Rajewsky K: Regulation of the germinal center
response by microRNA-155. Science 2007, 316:604-608.
9. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van
Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ,
Dougan G, Turner M, Bradley A: Requirement of bic/microRNA-155 for
normal immune function. Science 2007, 316:608-611.
10. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O,
Brummelkamp TR, Fleming MD, Camargo FD: Regulation of progenitor cell
proliferation and granulocyte function by microRNA-223. Nature 2008,
451:1125-1129.
11. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K,
Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL:
Detection of elevated levels of tumour-associated microRNAs in serum
of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:
D672-675.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK: Circulating microRNAs
as stable blood-based markers for cancer detection. Proc Natl Acad Sci
USA 2008, 105:10513-10518.
13. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X,
Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P,
Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J,
Zhang CY: Characterization of microRNAs in serum: a novel class of
biomarkers for diagnosis of cancer and other diseases. Cell Res 2008,
18:997-1006.
14. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J,
Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB: Detection
of microRNA expression in human peripheral blood microvesicles. PLoS
One 2008, 3:e3694.
15. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO: Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
16. Admyre C, Johansson SM, Qazi KR, Filén JJ, Lahesmaa R, Norman M,
Neve EP, Scheynius A, Gabrielsson S: Exosomes with immune modulatory
features are present in human breast milk. J Immunol 2007,
179:1969-1978.
17. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M,
Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ: miR-181a is an intrinsic
modulator of T cell sensitivity and selection. Cell 2007, 129:147-161.
18. Papapetrou EP, Kovalovsky D, Beloeil L, Sant’angelo D, Sadelain M:
Harnessing endogenous miR-181a to segregate transgenic antigen
receptor expression in developing versus post-thymic T cells in murine
hematopoietic chimeras. J Clin Invest 2009, 119:157-168.
19. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic
lineage differentiation. Science 2004, 303:83-86.
20. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S,
Das PP, Miska EA, Rodriguez A, Bradley A, Smith KG, Rada C, Enright AJ,
Toellner KM, Maclennan IC, Turner M: microRNA-155 regulates the
generation of immunoglobulin class-switched plasma cells. Immunity
2007, 27:847-859.
21. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF: miR-150, a microRNA
expressed in mature B and T cells, blocks early B cell development
when expressed prematurely. Proc Natl Acad Sci USA 2007, 104:7080-7085.
22. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N,
Bender TP, Rajewsky K: MiR-150 controls B cell differentiation by
targeting the transcription factor c-Myb. Cell 2007, 131:146-159.
23. Lu TX, Munitz A, Rothenberg ME: MicroRNA-21 is up-regulated in allergic
airway inflammation and regulates IL-12p35 expression. J Immunol 2009,
182:4994-5002.
24. Oddy WH: The long-term effects of breastfeeding on asthma and atopic
disease. Adv Exp Med Biol 2009, 639:237-251.
doi:10.1186/1758-907X-1-7
Cite this article as: Kosaka et al.: microRNA as a new immune-regulatory
agent in breast milk. Silence 2010 1:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kosaka et al. Silence 2010, 1:7
http://www.silencejournal.com/content/1/1/7
Page 8 of 8
